HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
19
05
2022
accepted:
09
12
2022
revised:
29
11
2022
medline:
18
4
2023
pubmed:
28
12
2022
entrez:
27
12
2022
Statut:
ppublish
Résumé
Integration of high-dimensional tumor gene expression data with clinicopathological data can increase our understanding of disease diversity, enable retrospective patient stratification, and identify new potential biomarkers and therapeutic targets. Using a systems biology approach, we provide a holistic overview of gene co-expression networks in head and neck squamous cell carcinomas (HNSCC). Weighted gene co-expression network analysis of HNSCC RNA sequencing data from 519 patients from The Cancer Genome Atlas (TCGA) was used to determine correlates of 5-year survival, using regression tree-based optimal threshold calculations. Survival-associated gene sets were transformed to gene set scores that were assessed for correlation with clinicopathological data. We identified 8 gene co-expression modules for HNSCC tumors, each of which contained co-expressed genes associated significantly with 5-year survival. Survival-associated co-expression gene signatures correlated dominantly with tumor HPV and p16 status. Network analysis identified that survival was associated with signaling networks of infection, immunity, epithelial-mesenchymal transition (EMT), hypoxia, glycolysis, focal adhesion, extracellular matrix, MYC signaling, autophagy and transcriptional regulation. EMT-associated gene signatures were expressed dominantly in fibroblasts, and cancer-associated fibroblasts were inversely correlated with immune activity. Interestingly, a high Immune Suppression Score based on expression of 21 genes associated with immune inhibition and including immune checkpoints, cytokines and regulatory T cell factors, was also associated with increased survival probability, and was significantly higher in HPV+ HNSCC. Networks associated with HNSCC survival were further associated with survival in cervical cancer, melanoma and lung cancer. This study defines 5129 genes associated with HNSCC survival, organized into co-expressed networks, their correlation with clinicopathological data, and with gene expression data from other malignant diseases, and provides a source for the discovery of biomarkers and novel therapies for HNSCC.
Identifiants
pubmed: 36575316
doi: 10.1038/s41417-022-00577-9
pii: 10.1038/s41417-022-00577-9
pmc: PMC10104777
doi:
Substances chimiques
Proto-Oncogene Proteins c-myc
0
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-640Informations de copyright
© 2022. The Author(s).
Références
Nat Commun. 2020 Jan 24;11(1):515
pubmed: 31980601
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
J Stat Softw. 2012 Mar;46(11):
pubmed: 23050260
J Gen Virol. 2021 Mar;102(3):
pubmed: 33427604
Mol Cancer. 2021 Apr 29;20(1):73
pubmed: 33926453
Sci Rep. 2022 Nov 4;12(1):18710
pubmed: 36333579
Laryngoscope. 2019 Nov;129(11):2506-2513
pubmed: 30637762
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690
Cell Death Discov. 2017 Nov 13;3:17071
pubmed: 29152378
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Cells. 2020 Apr 04;9(4):
pubmed: 32260326
Oral Dis. 2015 Apr;21(3):283-91
pubmed: 24797102
J Exp Med. 2007 Jun 11;204(6):1257-65
pubmed: 17502665
BMC Bioinformatics. 2018 Nov 6;19(1):404
pubmed: 30400809
Radiol Clin North Am. 2021 Sep;59(5):773-788
pubmed: 34392918
Mol Cancer. 2021 Jan 4;20(1):3
pubmed: 33397405
Nature. 2005 Jul 7;436(7047):123-7
pubmed: 16001073
Oral Oncol. 2016 Jul;58:8-13
pubmed: 27311396
Clin Cancer Res. 2008 Jul 15;14(14):4584-92
pubmed: 18628473
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Exp Mol Pathol. 2011 Apr;90(2):215-25
pubmed: 21236253
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Oncogene. 2019 Jun;38(25):4887-4901
pubmed: 30816343
Front Mol Biosci. 2021 Mar 23;8:622643
pubmed: 33834038
Laryngorhinootologie. 2018 Mar;97(S 01):S48-S113
pubmed: 29905354
J Oral Pathol Med. 2009 Nov;38(10):759-63
pubmed: 19453846
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Int J Mol Sci. 2020 Oct 30;21(21):
pubmed: 33143224
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Br J Radiol. 2019 Jan;92(1093):20180047
pubmed: 29493265
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Front Oncol. 2020 Nov 27;10:565306
pubmed: 33330034
Oncoimmunology. 2020 Apr 9;9(1):1744946
pubmed: 33457090
iScience. 2021 Mar 26;24(4):102368
pubmed: 33889830
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Cancer Cell Int. 2020 Oct 12;20:500
pubmed: 33061852
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593